In 2023, the American Academy of Pediatrics published a clinical practice guideline recommending weight-loss medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, as a supplement ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Ozempic and Wegovy are increasingly available in Australia and worldwide to treat type 2 diabetes and obesity.

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

For people with diabetes, the use of GLP-1 RAs is associated with reduced risk for certain disorders and conditions.

U.S. drugmaker Pfizer PFE.N is going “all in” to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla said at the JPMorgan ...

In 2022, pharmaceutical giant Pfizer (NYSE: PFE) became the first healthcare company to generate $100 billion in annual sales ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

A letter from several Democratic Senators urged Trump to use his deal-making skills to “flat out reject any request to end ...

A group of lawmakers are urging President Donald Trump to reject pharmaceutical companies’ efforts to pause the Biden ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity ...